Chemoimmunotherapy of murine bladder cancer

B. J. Stogdill, D. L. Lamm, R. B. Livingston

Research output: Contribution to journalArticle

Abstract

The lethality of invasive transitional cell carcinoma (TCC) has prompted a search for effective, minimally toxic, adjuvant therapy. Such agents were evaluated in a murine bladder cancer (MBT2) model which parallels the clinical disease. One hundred C3H/He mice were inoculated i.d. with 2.5 x 104 viable MBT2 tumor cells and randomized to receive either normal saline (control), cis-platinum (CPT), cyclophosphamide (CY), methotrexate (MTX), BCG, (CY + MTX), or (CY + MTX + BCG). Chemotherapy was given intraperitoneally weekly starting on day 7 after inoculation. Immunotherapy was given intralesionally on days 1 and 10 only. All mice were treated for 5 weeks followed by 5 weeks of observation. At 5 weeks, tumors of mice receiving cyclophosphamide alone or either of the combinations of therapy were smaller (P < 0.01) than tumors of controls or other single agents alone. Each regimen increased survival, but only the combination regimen increase survival significantly (P < 0.01). In the doses and schedule used in this model, combination chemotherapy and chemoimmunotherapy significantly delay tumor growth and increase duration of survival (P < 0.01) when compared with controls or single agent groups.

Original languageEnglish (US)
Pages (from-to)179-181
Number of pages3
JournalInvestigative Urology
Volume19
Issue number3
StatePublished - Dec 1 1981

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Chemoimmunotherapy of murine bladder cancer'. Together they form a unique fingerprint.

  • Cite this

    Stogdill, B. J., Lamm, D. L., & Livingston, R. B. (1981). Chemoimmunotherapy of murine bladder cancer. Investigative Urology, 19(3), 179-181.